Innovent Biologics Inc
HKEX:1801
Intrinsic Value
Innovent Biologics, Inc. is an investment company, which engages in the development and manufacture of biopharmaceutical products. [ Read More ]
The intrinsic value of one
Innovent Biologics Inc
stock under the Base Case scenario is
38.95
HKD.
Compared to the current market price of 33.2 HKD,
Innovent Biologics Inc
is
Undervalued by 15%.
Innovent Biologics Inc's market capitalization is 53.8B HKD.
Innovent Biologics Inc stock price is 33.2 HKD.
Innovent Biologics Inc stock price (33.2 HKD) is 15% less than its Intrinsic Value (38.95 HKD).
Innovent Biologics Inc stock (12.97 HKD) is 61% less than its price (33.2 HKD). Open DCF Valuation
Innovent Biologics Inc stock price (33.2 HKD) is 49% less than its Relative Value (64.93 HKD). Open Relative Valuation
Innovent Biologics Inc has upside potential of 70% compared to the average analyst price target.
Open Wall St Estimates
Innovent Biologics Inc's ROIC (Return on Invested Capital) has increased in the last 3 years from -16% to -11%, and is approaching profitability.
Innovent Biologics Inc's ROE (Return on Equity) has increased in the last 3 years from -15% to -9%, and is approaching profitability.
Innovent Biologics Inc's Revenue has grown by an exceptional 36% over the past 12 months.
Innovent Biologics Inc's Revenue has been growing by 17% per year for the last 3 years.
Innovent Biologics Inc's ROE (Return on Equity) for the past 12 months is negative and is equal to -9%.
Innovent Biologics Inc's Revenue is forecast to grow at a rate of 28% per year over the next 3 years.
Innovent Biologics Inc's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -11%.
Innovent Biologics Inc has negative Operating Income for the last twelve months.
Innovent Biologics Inc has negative Net Income for the last twelve months.
Innovent Biologics Inc's long-term assets (21B CNY) exceed its long-term liabilties (8B CNY).
Innovent Biologics Inc has positive Gross Profit for the last twelve months.
Innovent Biologics Inc's short-term assets (13B CNY) exceed its short-term liabilties (4B CNY).
Innovent Biologics Inc has negative Free Cash Flow for the last twelve months.
Innovent Biologics Inc's D/E (Debt to Equity) is very low and is equal to 0.19.
Innovent Biologics Inc has negative three-year average ROE (Return on Equity): -18%. The company is not efficient at transforming stockholders' equity into net income.
Innovent Biologics Inc has negative three-year average ROIC (Return on Invested Capital): -29%. The company is not efficient at using invested capital to generate operating income.
Innovent Biologics Inc has negative Net Debt. This means that the company has more cash and short-term investments (11B CNY) than debt (2B CNY).
Innovent Biologics Inc's Altman Z-Score is very high and is equal to 6.
Innovent Biologics Inc doesn't generate enough operating income (-1B CNY) to safely cover interest payments on its debt (115m CNY).
Valuation Backtest
Innovent Biologics Inc
Run backtest to discover the historical profit from buying and selling
Innovent Biologics Inc
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Innovent Biologics Inc
Balance Sheet Decomposition
Innovent Biologics Inc
| Current Assets | 13.4B |
| Cash & Short-Term Investments | 11B |
| Receivables | 1B |
| Other Current Assets | 1.5B |
| Non-Current Assets | 7.2B |
| Long-Term Investments | 794.1m |
| PP&E | 4.9B |
| Intangibles | 1.3B |
| Other Non-Current Assets | 283.1m |
| Current Liabilities | 4.5B |
| Accounts Payable | 372.5m |
| Other Current Liabilities | 4.1B |
| Non-Current Liabilities | 3.6B |
| Long-Term Debt | 2.4B |
| Other Non-Current Liabilities | 1.2B |
Earnings Waterfall
Innovent Biologics Inc
|
Revenue
|
6.2B
CNY
|
|
Cost of Revenue
|
-1.1B
CNY
|
|
Gross Profit
|
5.1B
CNY
|
|
Operating Expenses
|
-6.1B
CNY
|
|
Operating Income
|
-1.1B
CNY
|
|
Other Expenses
|
47.7m
CNY
|
|
Net Income
|
-1B
CNY
|
Free Cash Flow Analysis
Innovent Biologics Inc
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Innovent Biologics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Innovent Biologics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Innovent Biologics Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Score
Innovent Biologics Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Innovent Biologics Inc
According to Wall Street analysts, the average 1-year price target for
Innovent Biologics Inc
is 56.48 HKD
with a low forecast of 32.42 HKD and a high forecast of 80.85 HKD.
Shareholder Return
Price
Innovent Biologics Inc
| Average Annual Return | 36.43% |
| Standard Deviation of Annual Returns | 111.48% |
| Max Drawdown | -82% |
| Market Capitalization | 53.8B HKD |
| Shares Outstanding | 1 622 580 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Innovent Biologics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Innovent Biologics, Inc. is an investment company, which engages in the development and manufacture of biopharmaceutical products. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2018-10-31. The firm and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The firm's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The firm's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.
Contact
IPO
Employees
Officers
The intrinsic value of one
Innovent Biologics Inc
stock under the Base Case scenario is
38.95
HKD.
Compared to the current market price of 33.2 HKD,
Innovent Biologics Inc
is
Undervalued by 15%.
You don't have any saved screeners yet
